As these drugs are used to prevent, or treat, specific adverse effects of certain antineoplastic agents or radiotherapy, the risk of their use in breastfeeding is linked more to the risks of the associated radio/chemotherapy than their own inherent toxicity. In most cases suspension of breastfeeding during radio/chemotherapy would eliminate any risk from these drugs to the infant if breastfeeding is resumed. However, the risks from the associated antineoplastic agents must be considered before breastfeeding is resumed.